Press Releases

To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.

Initiator Pharma A/S announces outcome of rights issue

Initiator Pharma A/S (“Initiator Pharma” or the “Company”) today announces the outcome of the rights issue, for which the subscription period ended on 30 June 2022 (the “Rights Issue”). The outcome shows that 2,264,182 shares, corresponding to approximately 41.4 percent of the Rights Issue, were subscribed for with support of subscription rights (incl. pre-subscription commitments). In addition, subscription of 44,683 shares without support of subscription rights, corresponding to approximately 0.9 percent of the Rights Issue, have been received. In total, the subscription (incl. pre-subscription commitments) amounts to approximately 42.3 percent of the Rights Issue. Hence, underwriting commitments of 3,154,561 shares, corresponding to approximately 57.7 percent of the Rights Issue, will be utilized. Initiator Pharma will be provided approximately SEK 41 million before deduction of transaction related costs. Settlement notes are expected to be sent out today, 5 July 2022.

Issuance of new shares, share buyback and sale of shares in connection with long term incentive program for 2021

The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808,(“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2021 (“LTI2021-program”) and to conduct a buyback of shares in order to sell shares to the board of directors under the LTI2021-program.

The subscription period in Initiator Pharma AB’s rights issue begins today

Today, 16 June 2022, is the first day of the subscription period in Initiator Pharma A/S’s (“Initiator Pharma” or “the Company”) share issue, with preferential rights for existing shareholders (the “Rights Issue”). The public is also invited to subscribe for shares in the Rights Issue. The subscription period runs until, and including, 30 June 2022. The Rights Issue is fully secured through subscription and underwriting commitments and will provide the Company with approximately SEK 41 million before deduction of transaction related costs. The prospectus and a summary teaser are available on the websites of the Company (www.initiatorpharma.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se). Subscription forms can be obtained from Nordic Issuing AB’s website. In addition, it is possible to subscribe for shares digitally through Nordic Issuing AB’s website.

Initiator Pharma A/S publishes prospectus

Initiator Pharma A/S (“Initiator Pharma” or the “Company”) today publishes the prospectus relating to the Company’s upcoming rights issue. The prospectus has today been approved and registered by the Danish Financial Supervisory Authority and has been made available on Initiator Pharma’s website, http://www.initiatorpharma.com/investors/prospectuses. The prospectus is also available on the websites of Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se) and will be made available at the Danish Financial Supervisory Authority’s website. The subscription period for the rights issue will take place 16-30 June 2022.

Board of Directors decides on execution of rights issue

The Board of Directors of Initiator Pharma A/S (“Initiator” or the “Company”) has today, 31 May 2022, with authorization from the recently held Extraordinary General Meeting, resolved to carry out a fully secured share issue of approx. SEK 41 million with preferential rights for existing shareholders, in accordance with the previously published press release on 13 April 2022 (the “Rights Issue”). Through this press release, Initiator also announces the indicative timetable for the Rights Issue.

Board of Directors decides on execution of already communicated directed issue

The Board of Directors of Initiator Pharma A/S (“Initiator” or “the Company”) has today, 19 May 2022, based on the authorization from the recently held Extraordinary General Meeting, decided to execute the directed issue which was communicated via a press release on 13 April 2022. The directed issue was subscribed by Linc AB and Adrigo Asset Management AB, and it will provide the Company with approx. SEK 20 million before issue costs.